Vera Therapeutics, Inc. - VERA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 01, 2026 | SCHEDULE 13G | Point72 Asset Management, L.P. | 1.7% | 1,229,525 | View |
| Apr 01, 2026 | SCHEDULE 13G | Point72 Capital Advisors, Inc. | 1.7% | 1,229,525 | View |
| Apr 01, 2026 | SCHEDULE 13G | Steven A. Cohen | 1.7% | 1,229,525 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Mar 11, 2026 | SCHEDULE 13G | Deep Track Capital, LP | 5.5% | 3,921,362 | View |
| Mar 11, 2026 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 5.5% | 3,921,362 | View |
| Mar 11, 2026 | SCHEDULE 13G | David Kroin | 5.5% | 3,921,362 | View |
| Mar 05, 2026 | SCHEDULE 13D/A | — | 5.0% | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 7.7% | 5,461,988 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | FMR LLC | 4.1% | 2,885,853 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 4.1% | 2,885,853 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.03% | 3,570,401 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 5.7% | 3,666,598 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.